Monoclonal Clinical Trials

39 recruitingLast updated: May 21, 2026

There are 39 actively recruiting monoclonal clinical trials across 24 countries. Studies span Phase 2, Not Applicable, Phase 1, Early Phase 1, Phase 3. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Harrison, New York, United States. Updated daily from ClinicalTrials.gov.


Monoclonal Trials at a Glance

39 actively recruiting trials for monoclonal are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 2 with 11 trials, with the heaviest enrollment activity in Boston, New York, and Harrison. Lead sponsors running monoclonal studies include Mayo Clinic, Memorial Sloan Kettering Cancer Center, and Gruppo Italiano Malattie EMatologiche dell'Adulto.

Browse monoclonal trials by phase

About Monoclonal Clinical Trials

Looking for clinical trials for Monoclonal? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Monoclonal trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Monoclonal clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 39 trials

Recruiting

Study of Factors Regulating Mast Cell Proliferation

MastocytosisMonoclonalBone Marrow+1 more
National Institute of Allergy and Infectious Diseases (NIAID)600 enrolled1 locationNCT00044122
Recruiting

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Smoldering Multiple MyelomaMyelodysplastic SyndromesWaldenstrom Macroglobulinemia+5 more
Dana-Farber Cancer Institute10,000 enrolled7 locationsNCT02269592
Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting
Not Applicable

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami120 enrolled1 locationNCT07446777
Recruiting

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)Multiple Myeloma (MM)
Azienda USL Reggio Emilia - IRCCS60 enrolled4 locationsNCT07214324
Recruiting

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center200 enrolled1 locationNCT02726750
Recruiting
Phase 2

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

IgA Monoclonal Gammopathy of Undetermined Significance
Fred Hutchinson Cancer Center50 enrolled1 locationNCT07209371
Recruiting
Not Applicable

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center180 enrolled8 locationsNCT05640843
Recruiting
Phase 2

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Multiple MyelomaMonoclonal Gammopathy of Renal Significance
Memorial Sloan Kettering Cancer Center20 enrolled11 locationsNCT06083922
Recruiting

Pre-malignant States to Hematologic Malignancies in Firefighters

Non-Hodgkin LymphomaMultiple MyelomaLeukemia+3 more
Wake Forest University Health Sciences300 enrolled1 locationNCT06870760
Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple MyelomaAL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia760 enrolled4 locationsNCT06383143
Recruiting

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Plasma Cell Myeloma
M.D. Anderson Cancer Center400 enrolled1 locationNCT05136807
Recruiting
Phase 2

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)
Regeneron Pharmaceuticals116 enrolled20 locationsNCT06140524
Recruiting

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami1,000 enrolled1 locationNCT05361694
Recruiting

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

Chronic Lymphocytic LeukemiaMonoclonal B-Cell Lymphocytosis
Mayo Clinic50 enrolled1 locationNCT06536452
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceAL Amyloidosis+1 more
Ohio State University Comprehensive Cancer Center5,000 enrolled1 locationNCT01408225
Recruiting

Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment

Multiple MyelomaMGUSAL Amyloidosis+1 more
Fondazione IRCCS Policlinico San Matteo di Pavia100 enrolled1 locationNCT07448779
Recruiting
Phase 3

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499